Astrazeneca (AZN) Long-Term Deferred Tax (2009 - 2026)

Astrazeneca has reported Long-Term Deferred Tax for 18 years, with the latest figure at $6.5 billion in Q2 2026.

• On a quarterly basis, Long-Term Deferred Tax rose 3.69% year-over-year to $6.5 billion in Q2 2026; TTM through Jun 2026 was $6.5 billion, a 3.69% increase from a year earlier, with the FY2025 full-year figure at $5.8 billion, up 8.83% from the prior year.
• Long-Term Deferred Tax was $6.5 billion for Q2 2026 at Astrazeneca, up from $5.6 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $6.5 billion in Q2 2026, with the low at $3.3 billion in Q4 2022.
• Average Long-Term Deferred Tax over 5 years is $4.9 billion, with a median of $4.7 billion recorded in 2023.
• The sharpest annual moves came in 2022 and 2023: Long-Term Deferred Tax decreased 24.64% in 2022, then jumped 44.59% in 2023.
• Over 5 years, Long-Term Deferred Tax stood at $3.3 billion in 2022, then surged by 44.59% to $4.7 billion in 2023, then advanced by 13.33% to $5.3 billion in 2024, then grew by 8.83% to $5.8 billion in 2025, then climbed by 11.48% to $6.5 billion in 2026.
• The last three Long-Term Deferred Tax figures came in at $6.5 billion (Q2 2026), $5.6 billion (Q1 2026), and $5.8 billion (Q4 2025), per Business Quant data.